Literature DB >> 990250

Proteolytic activation of protein C from bovine plasma.

W Kisiel, L H Ericsson, E W Davie.   

Abstract

Protein C is a vitamin K dependent protein present in bovine plasma (Stenflo, J. (1976), J. Biol. Chem. 251, 355). It is a glycoprotein (mol wt approximately 62 000) composed of a heavy chain (mol wt 41 000) and a light chain (mol wt 21 000). The heavy chain has an amino-terminal sequence of Asp-Thr-Asn-Gln and contains nearly three-fourths of the carbohydrate. The light chain has an amino-terminal sequence of Ala-Asn-Ser-Phe. Incubation of protein C with either factor X activator from Russell's viper venom or trypsin resulted in the cleavage of an Arg-Ile bond between residues 14 and 15 of the heavy chain. Concomitant with this cleavage was the formation of a serine enzyme which was inhibited by diisopropyl phosphorofluoridate. Liberation of the tetradecapeptide decreased the molecular weight of the heavy chain from about 41 000 to 39 000 and resulted in the formation of a new amino-terminal sequence of Ile-Val-Asp-Gly in the heavy chain. No change in the molecular weight of the light chain was observed during the activation reaction. These results indicate that protein C, like the four vitamin K dependent coagulation proteins, exists in plasma in a precursor form and is converted to a serine protease by hydrolysis of a specific Arg-Ile peptide bond. The biological substrate for the enzymatic form of protein C and the physiological mechanism whereby protein C is converted to a serine enzyme are not known.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 990250     DOI: 10.1021/bi00667a022

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

1.  Myeloid/natural killer cell precursor acute leukemia accompanied by homozygous protein C deficiency.

Authors:  Takashi Shimamoto; Akihiro Nakajima; Tomoko Katagiri; Yoshikazu Ito; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

2.  Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1.

Authors:  Lea M Beaulieu; Frank C Church
Journal:  Exp Cell Res       Date:  2006-12-14       Impact factor: 3.905

3.  Modeling zymogen protein C.

Authors:  L Perera; C Foley; T A Darden; D Stafford; T Mather; C T Esmon; L G Pedersen
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

4.  Estimation of the distance between the divalent cation binding site of des-1-41-light chain-activated bovine plasma protein C and a nitroxide spin label attached to the active-site serine residue.

Authors:  K A Hill; S A Steiner; F J Castellino
Journal:  Biochem J       Date:  1988-04-01       Impact factor: 3.857

5.  beta-Hydroxyaspartic acid in vitamin K-dependent protein C.

Authors:  T Drakenberg; P Fernlund; P Roepstorff; J Stenflo
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

6.  Comparison of amino acid sequence of bovine coagulation Factor IX (Christmas Factor) with that of other vitamin K-dependent plasma proteins.

Authors:  K Katayama; L H Ericsson; D L Enfield; K A Walsh; H Neurath; E W Davie; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

7.  Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.

Authors:  W M Canfield; W Kisiel
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

8.  Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease.

Authors:  R A Marlar; J H Griffin
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

9.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

10.  The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.

Authors:  R G DiScipio
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.